Evaluation of Treatment Outcomes Using dNLR and GNRI in Combination Therapy With Atezolizumab and Bevacizumab for Hepatocellular Carcinoma

Evaluation of Treatment Outcomes Using dNLR and GNRI in Combination Therapy With Atezolizumab and Bevacizumab for Hepatocellular Carcinoma

ABSTRACT Aim This study aims to investigate the clinical utility of the derived neutrophil‐to‐lymphocyte ratio (dNLR) and the Geriatric Nutritional Risk Index (GNRI) in predicting treatment outcomes for patients with unresectable hepatocellular carcinoma (HCC) undergoing combination therapy with ate...

Full description

Saved in:
Bibliographic Details
Main Authors: Atsushi Naganuma, Satoru Kakizaki, Atsushi Hiraoka, Toshifumi Tada, Takeshi Hatanaka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hidenori Toyoda, Chikara Ogawa, Hiroki Nishikawa, Takashi Nishimura, Kazuhito Kawata, Hisashi Kosaka, Masashi Hirooka, Yutaka Yata, Hideko Ohama, Hidekatsu Kuroda, Tomomitsu Matono, Tomoko Aoki, Yuki Kanayama, Kazunari Tanaka, Fujimasa Tada, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Shinichiro Nakamura, Hirayuki Enomoto, Masaki Kaibori, Yoichi Hiasa, Masatoshi Kudo, Takashi Kumada
Format: Article
Language:English
Published: Wiley 2025-01-01
Series:Cancer Medicine
Subjects:
dNLR
GNRI
hepatocellular carcinoma
immune checkpoint inhibitor
prognosis
Online Access:https://doi.org/10.1002/cam4.70618
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items